The role of the vehicle in combination acne therapy

Cutis

Volumn 76, Issue 2 SUPPL., 2005, Pages 15-18

  Del Rosso, James Q ^a,b,c,d,e  

^a UNIVERSITY OF NEVADA   (United States)

^b ALLERGAN INC   (United States)

^c Galderma Laboratories   (United States)

^d Medicis Pharmaceutical Corporation   (United States)

^e Stiefel Laboratories Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; EMOLLIENT AGENT; KERATOLYTIC AGENT; MICROSPHERE; RETINOIC ACID;

ACNE VULGARIS; ARTICLE; DRUG COMBINATION; DRUG DELIVERY SYSTEM; GEL; HUMAN;

ACNE VULGARIS; CLINDAMYCIN; DRUG DELIVERY SYSTEMS; DRUG THERAPY, COMBINATION; EMOLLIENTS; GELS; HUMANS; KERATOLYTIC AGENTS; MICROSPHERES; TRETINOIN;

EID: 24744456930     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Russell JJ. Topical therapy for acne. Am Fam Physician. 2000;61:357-366.
2. Weiss JS, Shavin JS. Topical retinoid and antibiotic combination therapy for acne management. J Drugs Dermatol. 2004;3:146-154.
3. Woodard I. Adolescent acne: a stepwise approach to management. Top Adv Pract Nurse J [serial online]. Available at: http://www.medscape.com/ viewarticle/430534. Accessed July 7, 2005.
4. Thiboutot D. New treatments and therapeutic strategies for acne. Arch Fam Med. 2000;9:179-187.
5. Jappe U. Pathological mechanisms of acne with special emphasis on Propionibacterium acnes and related therapy. Acta Derm Venereol. 2003;83:241-248.
6. Effendy I, Weltfriend S, Patil S, et al. Differential irritant skin responses to topical retinoic acid and sodium lauryl sulphate: alone and in crossover design. Br J Dermatol. 1996;134:424-430.
7. Berson DS, Chalker DK, Harper JC, et al. Current concepts in the treatment of acne: report from a clinical roundtable. Cutis. 2003;72(suppl 1):5-13.
8. Draelos ZD. Therapeutic moisturizers. Dermatol Clin. 2000;18:597-607.
9. Longshore SJ, Hollandsworth K. Acne vulgaris: one treatment does not fit all. Cleve Clin J Med. 2003;70:670-680.
10. Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49:S1-S37.
11. Webster GF. Topical tretinoin in acne therapy. J Am Acad Dermatol. 1998;39(suppl 2, pt 3):S38-S44.
12. Lucky A, Cullen S, Funicella T, et al. Double-blind, vehicle-controlled, multicenter comparison of two 0.025% tretinoin creams in patients with acne vulgaris. J Am Acad Dermatol. 1998;38:S24-S30.
13. Lucky A, Cullen S, Jarratt M, et al. Comparative efficacy and safety of two 0.025% tretinoin gels: results from a multicenter, double-blind, parallel study. J Am Acad Dermatol. 1998;38:S17-S23.
14. Fagundes DS, Fraser JM, Klauda HC. Difference in the irritation potential and cosmetic acceptability of two combination topical acne gels - combined results of two comparative studies. Today's Ther Trends. 2003;21:269-275.
15. Tanghetti E, Gold M, Fraser J. A two-center patient preference study comparing two acne gels. Poster presented at: 63rd Annual Meeting of the American Academy of Dermatology; February 18-22, 2005; New Orleans, La. P108.
16. Shalita A, Tanghetti E, Abramovits W, et al. Tazarotene versus tazarotene plus clindamycin/benzoyl peroxide in the treatment of acne vulgaris: a multicenter, double-blind, randomized, parallel-group trial. Poster presented at: 63rd Annual Meeting of the American Academy of Dermatology; February 18-22, 2005; New Orleans, La. P147.
17. Draelos ZD, Tanghetti EA, and the Tazarotene Combination Leads to Efficacious Acne Results (CLEAR) Trial Study Group. Optimizing the use of tazarotene for the treatment of facial acne vulgaris through combination therapy. Cutis. 2002;69(suppl 2):20-29.